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Background:Measuring patient-centered outcomes is becoming increasingly important in patients with peripheral arterial
disease (PAD), both as a means of determining the benefits of treatment and as an aid for disease management. In order
to monitor health status in a reliable and sensitive way, the disease-specific measure Peripheral Artery Questionnaire
(PAQ) was developed. However, to date, its correlation with traditional clinical indices is unknown. The primary aim of
this study was to better establish the clinical validity of the PAQ by examining its association with functional indices
related to PAD. Furthermore, we hypothesized that the clinical validity of this disease-specific measure is better as
compared with the EuroQol-5-dimensional (EQ-5D), a standardized generic instrument.
Methods: Data on 711 consecutive PAD patients undergoing surgery were collected from 11 Dutch hospitals in 2004. At
3-year follow-up, questionnaires including the PAQ, EQ-5D, and EuroQol-Visual Analogue Scale (EQ VAS) were
completed in 84% of survivors. The PAQ was analyzed according to three domains, as established by a factor analyses in
the Dutch population, and the summary score. Baseline clinical indices included the presence and severity of claudication
intermittent (CI) and the Lee Cardiac Risk Index.
Results: All three PAQ domains (Physical Function, Perceived Disability, and Treatment Satisfaction) were significantly
associated with CI symptoms (P values < .001-.008). Patients with claudication had significant lower PAQ summary
scores as compared with asymptomatic patients (58.6  27.8 vs 68.6  27.8, P  < .001). Furthermore, the PAQ
summary score and the subscale scores for Physical Functioning and Perceived Disability demonstrated a clear
dose-response relation for walking distance and the Lee Risk Index (P values < .001-.031). With respect to the generic
EQ-5D, the summary EQ-5D index was associated with CI (0.81 0.20 vs 0.76 0.24, P .031) but not with walking
distance (P  .128) nor the Lee Risk Index (P  .154). The EQ VAS discriminated between the clinical indices (P val-
ues  .003-.008), although a clear dose-response relation was lacking.
Conclusion: The clinical validity of the PAQ proved to be good as the PAQ subscales discriminated well between patients
with or without symptomatic PAD and its severity as defined by walking distance. Furthermore, the PAQ subscales were
directly proportional to the presence and number of risk factors relevant for PAD. For studying outcomes in PAD
patients, the disease-specific PAQ is likely to be a more sensitive measure of treatment benefit as compared with the
generic EQ VAS, although the latter may still be of value when comparing health status across different diseases.
Regarding disease management, we advocate the use of the disease-specific PAQ as its greater sensitivity and validity will
assist its translation into clinical practice. ( J Vasc Surg 2009;49:371-7.)Peripheral arterial disease (PAD) is a common chronic
condition and is associated with increased cardiovascular
morbidity and mortality.1 The global aging phenomenon
will further increase the burden of cardiovascular diseases,
including PAD.2 It is well accepted that PAD adversely
affects patients’ health status and quality of life (QoL).3
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Vascular Surgery.doi:10.1016/j.jvs.2008.08.089Patients not only perceive that their physical functioning is
affected by lower-extremity symptoms, but a PAD diagno-
sis and its associated symptoms also affect patients’ psycho-
logical well-being and mental health.4-6
The primary treatment goals of patients with PAD are
to relieve pain, improve health status and QoL, and pro-
long survival. Measuring sensitive patient-centered out-
come measures is becoming increasingly used in order to
quantify the benefits of different treatment strategies and
their cost-effectiveness.7 From a methodological perspec-
tive, these measures are important because the discrimina-
tive power of mortality as an outcome measure is poor,
especially in PAD where mortality is more often due to the
associated coronary and cerebrovascular disease rather than
the PAD itself. As such, treatment of PAD is more often
directed towards the goal of improving symptoms and its
associated health impact, rather than survival. In addition
to using health status in outcomes research, health status
measurements can be used in disease management as a tool
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or who are at higher risk for adverse outcomes.8 Identifica-
tion of these high-risk patients may lead to more invasive
treatment and more intensive follow-up.
Health status and QoL can be assessed using either
generic or disease-specific instruments. Available data sug-
gests a better construct validity of disease-specific instru-
ments as compared with generic instruments.9 Key advan-
tages of disease-specific instruments are the focus on
specific symptoms of a disease and their correspondingly
greater sensitivity and responsiveness to clinical changes.
Furthermore, the information received from disease-
specific instruments can also be more easily translated into
clinical practice as compared with information derived from
generic questionnaires. On the other hand, advantages of
using generic instruments are their simplicity and the ability
of comparing patients’ health status across different dis-
eases.
In order to monitor health status in a reliable way, a
new disease-specific measure, the Peripheral Artery Ques-
tionnaire (PAQ), was developed in US patients undergoing
percutaneous peripheral revascularization and afterwards
translated and validated in Dutch using a vascular surgery
population in The Netherlands.10 Although its psychomet-
ric properties10,11 and sensitivity to change after revascular-
ization12 were adequately documented, there is limited
insight into the ability to discriminate between asymptom-
atic and symptomatic disease and its correlation with tradi-
tional clinical indices of disease severity.10,12 This study was
designed to further document its validity by contrasting
PAQ scores in patients with asymptomatic and symptom-
atic disease and by comparing PAQ scores with PAD-
related indices, such as walking disease and an established
cardiac risk algorithm. More specifically, clinical validity
was studied both in this disease-specific instrument and the
EQ-5D, a standardized generic instrument applicable in a
wide range of medical conditions, containing a 5-dimen-
sional descriptive health status system (EQ-5D) and a visual
analogue scale (EQ VAS).13,14 We hypothesized that the
clinical validity of the disease-specific PAQ would be better
than the generic EQ-5D.
METHODS
Study population. Between May and December
2004, a survey of clinical practice was conducted in 11
hospitals in The Netherlands.15 This survey was an integral
part of the infrastructure of the survey program supported
by TheNetherlandsHeart Foundation in the context of the
Euro Heart Survey Programme. All consecutive patients
included in this survey were seen at the participating vascu-
lar surgery departments and were undergoing noncardiac
vascular repair (endovascular or open procedures). Endo-
vascular procedures included aortic endograft procedures
and peripheral angioplasties with and without stenting.
Open procedures included abdominal aortic surgery, ca-
rotid endarterectomy, or infrainguinal arterial reconstruc-
tion. Patients below the age of 18 years and patients under-
going thoracic or brain surgery were excluded. The totalstudy population consisted of 711 consecutively enrolled
patients undergoing peripheral vascular repair. After 3 years
follow-up, information on survival status was obtained
through the Civil Registries. Patient status could be deter-
mined in 701 (99%) of the original 711 respondents reveal-
ing that 149 (21%) of patients had died in the 3-year period
since the original survey. All 552 survivors were contacted
to complete health status questionnaires (EQ-5D and
PAQ), 465 (84%) of whom responded and comprised the
final study group.
Clinical characteristics. Trained research assistants
obtained data on patient characteristics, cardiac treatments,
and the surgical procedure from the patients’ hospital
charts. We determined the cardiac risk score for each pa-
tient in our dataset, according to the Lee Risk Index,16 in
which one point is assigned to each of the following char-
acteristics: open vascular surgery, history of ischemic heart
disease, history of congestive heart failure, history of cere-
brovascular disease, insulin therapy for diabetes, and renal
failure. Furthermore, the presence of claudication and its
severity were assessed by quantifying patients’ maximum
walking distance. Walking distance was scored as 50
meters, 50-100 meters, or 100 meters. More details on
the study population and methods of data collection can be
found in an earlier publication on this survey.17
Health status. Health status was measured at 3 years
of follow-up by the translated Dutch version of the PAQ, a
disease-specific instrument for assessing health status in
patients with PAD. The instrument consists of 20 items
with one item identifying themost symptomatic leg and the
other items being answered along variable Likert scales
with equidistant gradations of response. Although the term
‘health status’ was chosen to refer to the construct that the
PAQ intends to measure, the questionnaire contains both
items that assess health status (ie, registration of limita-
tions) and QoL (patients’ personal evaluation of their func-
tioning, disease, and treatment). A previous validation
study of the Dutch PAQ revealed three overarching do-
mains: physical limitation (corresponding to the original
PAQ physical limitation domain), perceived disability (cor-
responding to the original PAQ symptom, symptom stabil-
ity, social limitation, and QoL domains), and treatment
satisfaction (corresponding to the original PAQ treatment
satisfaction domain). Given that the response categories are
different across items, standardized scoring algorithms are
applied to obtain scale scores ranging from 0 to 100, with
high scores indicating good health status.10 A summary
score can be obtained by combining the physical limitation
and perceived disability subscale scores. The PAQ and its
scoring instructions can be obtained from http://www.
cvoutcomes.org/.
The Dutch version of the EQ-5D was used as a stan-
dardized generic instrument for describing and valuing
health.13,14 This instrument was developed by the EuroQol
group and has been used to assess health status across a
wide range of chronic conditions, including cardiovascular
disease.17 The EQ-5D contains both an EQ-5D descriptive
system that defines health along five dimensions and an EQ
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of mobility, self-care, usual activities, pain or discomfort,
and anxiety/depression. Each of these dimensions has
three levels of severity corresponding to “no problems”,
“moderate problems”, and “severe problems”. Theoreti-
cally, 243 different health states can be generated by the
descriptive system. A single summary index (EQ-5D index)
representing the patients’ self-rated health can be calcu-
lated by applying scores from a standard set of general
population weights. The ratings can be analyzed on an
individual level using health-state utility scores. Scores 0
are regarded as worse than death and 1 representing full
health, from the perspective of the general population. The
EQ-5D index in this study was obtained on value sets
derived from the Dutch population by the time trade-off
valuation technique.14 In addition, the EQ VAS asks re-
spondents to rate their perception of their overall health on
a vertical visual analogue scale with the endpoints ranging
from 0 to 100 (0  ‘worst imaginable health state’ and
100  ‘best imaginable health state’). The EQ-5D and its
scoring instructions can be obtained from http://www.
euroqol.org/. The results of the EQ-5D in this study will be
presented using the weighted index of the 5-dimensional
descriptive system (EQ-5D index) and using the EQ VAS
as a measure of overall self-rated health status.
Clinical validity. Clinical validity assesses the ability of
scores to discriminate among groups of patients defined
according to clinical severity. Patients who have a good
clinical status (ie, asymptomatic disease, fewer risk factors,
and longer walking distance) should score well in the
questionnaire, and patients who have a poor clinical status
(ie, symptomatic disease, more risk factors, and shorter
walking distance) should score poorly. A high degree of
clinical validity is suggested by a high correlation between
health status and clinical indicators.
Statistical analyses. Baseline characteristics were de-
scribed as numbers and percentages. Health status scores
were described as means and standard deviations and com-
pared using t tests for dichotomous data and analysis of
variance (ANOVA) for multiple categories. Linear regres-
sion analysis was used to assess multivariable association
between the clinical indicators for PAD and health status
scores. For all tests, a P value  .05 (two-sided) was
considered significant. All statistical analyses were per-
formed using SPSS 15.0 statistical software (SPSS Inc,
Chicago, Ill).
RESULTS
Of the 465 participating patients, 454 had sufficient
health status information to generate PAQ summary scores
with a mean score of 62.0  28.2. Missing data analysis
showed that respondents did not differ significantly from
non-respondents with regard to age, gender, and Lee Risk
index. As shown in the Table, most cardiovascular risk
factors compromising the Lee Risk Index were associated
with lower PAQ summary scores. Furthermore, the pres-
ence of chronic obstructive pulmonary disease (COPD)
(53.3  26.8 vs 63.0  28.2, P  .024) and obesity(50.8 29.0 vs 63.6 27.8, P .001) was associated with
lower PAQ summary scores.
As shown in the Table and Fig 1, patients with claudi-
cation had significantly lower PAQ summary scores as
compared with asymptomatic patients (58.6  27.8 vs
68.6  27.8, P   .001). The differences in the PAQ
summary score reflect the observed differences in the un-
Table. Baseline characteristics
PAQ summary score
N (%) Mean SD P value
465
Age (yrs) .001
70 years 307 (66.0) 66.0 27.4
70 years 158 (34.0) 54.1 28.2
Gender .086
Male 323 (69.5) 63.5 28.3
Female 142 (30.5) 58.6 27.8
Diabetes mellitus .001
No 369 (79.4) 64.2 28.0
Yes 96 (20.6) 53.4 27.6
Renal insufficiency .035
No 441 (91.8) 62.7 28.1
Yes 24 (5.2) 50.2 27.9
Angina pectoris .005
No 392 (84.3) 63.6 27.6
Yes 73 (15.7) 53.6 29.9
Myocardial infarction .036
No 398 (85.6) 63.2 27.9
Yes 67 (14.4) 55.2 29.5
Heart failure .001
No 447 (96.1) 62.9 27.9
Yes 18 (3.9) 39.8 27.7
Stroke or TIA .172
No 356 (85.2) 62.8 27.9
Yes 69 (14.8) 57.8 29.6
Previous
revascularization
.048
No 388 (83.4) 63.2 28.4
Yes 77 (16.6) 56.2 26.5
Hypertension .830
No 288 (61.5) 61.8 27.7
Yes 177 (38.1) 62.4 29.1
Current smoker .554
No 300 (64.5) 62.6 27.5
Yes 165 (35.5) 61.0 29.4
COPD .024
No 416 (89.5) 63.0 28.2
Yes 49 (10.5) 53.3 26.8
Obesity .001
No 408 (87.7) 63.6 27.8
Yes 57 (12.3) 50.8 29.0
Claudication .001
No 160 (34.4) 68.6 27.8
Yes 305 (65.6) 58.6 27.8
Lee Risk Index .007
0 risk factors 141 (30.3) 86.1 25.4
1 risk factor 157 (33.8) 61.8 28.6
2 risk factors 131 (28.2) 57.8 29.2
3 risk factors 36 (7.7) 54.7 29.4
PAQ , Peripheral Artery Questionnaire,N, number; SD, standard deviation;
TIA, transient ischemic attack; COPD, chronic obstructive pulmonary dis-
ease.derlying PAQ domains Physical Functioning and Perceived
, Eur
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main successfully discriminated between those who were
symptomatic and those with asymptomatic PAD (75.0 
28.1 vs 82.5 25.7, P .008). With respect to the generic
EQ-5D, both the EQ-5D index and the EQ VAS scores
were lower for patients with claudication.
Of the 305 patients with claudication, information on
walking distance was available in 202 (73%) patients with
25% classified as 0-50 meters, 29% 50-100 meters, and 46%
more than 100meters. As shown in Fig 2, PAQ scores were
proportional higher with increasing walking ability. The
EQ VAS also differed significantly between the groups,
Fig 1. Health status according to presence of claudic
Questionnaire; EQ-5D, EuroQol-5-dimension; EQ VAS
Fig 2. Health status according to walking distance. Inform
patients with claudication intermittent (CI). PAQ , Periph
VAS, EuroQol visual analogue scale.while the differences in EQ-5D index lacked significance.PAQ summary score and subscale scores for the Physi-
cal Functioning domain and the Perceived Disability do-
main demonstrated a clear dose-response relationship with
the Lee Risk Index, ie, PAQ scores were lower with increas-
ing cardiac risk (Fig 3). The Treatment Satisfaction domain
was not associated with the Lee Risk Index. The EQ-5D
index did not differ significantly between the risk groups;
while the EQ VAS did (P  .008), although the clear
dose-response relation was lacking.
In addition, multivariable linear regression analysis
revealed that after adjusting for other clinical character-
istics, the independent association between CI, Lee Risk
intermittent (CI) symptoms. PAQ , Peripheral Artery
oQol visual analogue scale.
on walking distance was available in 202 (73%) of the 305
rtery Questionnaire; EQ-5D, EuroQol-5-dimension; EQationation
eral AIndex, and PAQ scores (Physical Functioning, Perceived
ue sca
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P values  .05).
DISCUSSION
This study demonstrated good clinical validity of the
PAQ with traditional clinical indices of PAD severity. In
specific, all PAQ subscales discriminated well between pa-
tients with or without symptomatic PAD and its severity.
Moreover, it was sensitive to the presence of risk factors
relevant for PAD and demonstrated a clear dose-response
relationship between the number of risk factors and pa-
tients’ experienced health status. Although the EQ-5D
index and EQ VAS scale could differentiate between
asymptomatic and symptomatic disease, the EQ indices
were not able to display the clear dose-response relation-
ship between the number of risk factors and worsening of
health status. These findings have important potential im-
plications for disease management programs and future
clinical trials.
An important issue to be addressed regarding the de-
velopment and use of health status instruments in vascular
medicine are their reliability and validity. Internal reliability
of the three domains quantified by Crohnbach’s  was
reported high for the Dutch PAQ (mean  0.94) and the
original instrument.10 Previous studies also showed that
the PAQ had a good test-retest reliability and sensitivity to
change.10,12 In addition, an important issue for the use of
disease-specific measures in clinical practice is that they
focus on aspects that are relevant for a specific patient
population. Our results of the PAQ instrument clearly
show the disease-specific nature of this measure, with the
PAQ discriminating well between different clinical indices.
The strongest associations of PAD symptoms that we ob-
served were with pain and physical limitations, ie, the PAQ
sub domains of Physical Functioning and Perceived Dis-
ability. This observation confirms earlier research demon-
Fig 3. Health status according to the Lee Cardiac R
EuroQol-5-dimension; EQ VAS, EuroQol visual analogstrating the impact of symptomatic disease on physicalhealth and QoL in PAD patients.5,18 PAD is also often
accompanied by comorbid diseases, which may pose an
extra burden on patients’ health status. The results in this
report showed that the cardiac risk profile of PAD patients,
as described by the Lee Cardiac Risk Index, was highly
correlated with patients’ health status. Increasing risk was
proportionally reflected in decreasing PAQ scores on the
Physical Functioning and Perceived Disability domains and
Summary score.
The management of patients with PAD has changed in
the last decade with the introduction of endovascular tech-
niques and other treatment modalities.19 In general, the
principal aim of medical treatment is to relieve symptoms
related to the specific disease and to improve the patient’s
health status and prognosis. Traditionally, treatment suc-
cess is measured with clinical measures, such as the ankle-
brachial index, patency rates, and survival. The question
regarding the impact of the intervention on the patients’
ability to function in daily life remains, however, when only
relying upon these technical measures.7 Since the patients’
main concerns are for symptom relief and improvement in
their daily functioning, treatment should also be assessed
by its success in improving patients’ health status. Further-
more, clinical measures, as the ankle-brachial index, are
known to correlate poorly with changes in health status
scores,9,20 which also supports the use of direct, patient-
centered assessments of the effects of treatment on patients’
health status. As such, health status is increasingly being
assessed in clinical research studies comparing different
treatment options.20,21 Moreover, patient-based outcome
measures can provide substantial insights into related clin-
ical factors and processes of care that are useful in assessing
health care quality.22 Traditional metrics for evaluating
health care have been mortality and morbidity, but these
measures often lack the sensitivity to differentiate providers
dex. PAQ , Peripheral Artery Questionnaire; EQ-5D,
le.isk Inand omit a major outcome from the perspective of patients.
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health status, important advantages of disease-specific, as
compared with generic, instruments are their focus on
specific symptoms of a disease and the sensitivity and re-
sponsiveness to clinically-relevant changes conferred by
treatment. Previous studies have demonstrated a better
discriminative ability of disease-specific vs generic question-
naires to detect changes in QoL in PAD patients,23 con-
gruent with the findings of our study, which demonstrated
that the PAQ discriminated better between the clinical
indices than the generic EQ-5D index. The EQ-5D is
known for its ceiling effect, ie, the score distribution tends
to be skewed to higher scores, which could potentially be
related to having only three response categories and its
generic character. In our study, 25% of the patients had a
maximum score. Except for patients with more than three
risk factors according to the Lee Risk Index, mean scores of
the EQ5D were all higher than 0.75 and did not differ
substantially. On the other hand, the EQ VAS was more
sensitive for clinical indices, although its discriminative
ability appeared to be less than the PAQ in this study. For
studying outcomes in PAD patients, the disease-specific
PAQ, therefore, seems to be the preferred choice. The EQ
VAS may still be a valuable secondary choice, as generic
health status questionnaires are known to be broad and
multidimensional instruments and, therefore, apt for use
when comparing health status across different diseases or
when calculating utility values in economic analysis are
important study goals.
In addition to using health status measures as outcome
measures, health status measurements may provide prog-
nostic information to guide clinical decision-making. In
this way, impaired health status has been shown to be an
independent predictor of mortality in cardiac patients24-26
and predicted invasive treatment in a prospective PAD
population.27 Health status measurements can, therefore,
potentially be used in clinical practice to identify patients
who are at relatively high risk for adverse outcomes. These
patients may benefit from more aggressive treatment, in-
cluding pharmacological, invasive, or behavioral interven-
tions. Of note, the performance of the EQ VAS score was
acceptable when discriminating between symptomatic vs
asymptomatic disease and suboptimal when relating the
index to walking distance and the presence of risk factors.
Although it seems attractive in terms of time, effort, and
resources to use this simple instrument to assess the pa-
tients’ health status, its role in disease management is
minor. The PAQ describes clear and clinically-relevant
domains that can give clinicians important insights with
which to better manage patients’ PAD; including patients’
physical limitations due to their PAD and their personal
evaluation of their limitations related to PAD. These nu-
ances can not be captured by generic questionnaires and by
instruments that only focus on physical limitations, rather
than concentrating on the subjective evaluations of pa-
tients’ physical functioning. Although information received
from generic instruments are hard to interpret and to
translate into clinical practice, the EQ VAS may be used asan initial screening tool to further identify vulnerable pa-
tients with disease-specific questionnaires, such as the PAQ.
The limitations of this study are those inherent to
observational studies and the fact that all patients under-
went vascular interventions. Although the study cohort
seems to be a relatively high-risk population, the PAQ was
still able to discriminate well between the clinical indices.
Moreover, it has to be noted that compared to clinical trials,
our study comprises a rather heterogeneous population and
is more representative of daily clinical practice. Further
research has to be performed to ascertain the clinical valid-
ity of PAQ in an overall PAD population treated with a
range of therapeutic options. Another potential limitation
of our work is that the response rate of our study was not
100%. A response rate of 84%, however, is regarded as quite
good and importantly non-responder analyses revealed no
differences between the patients who responded and those
who did not. Furthermore, it should be noted that the
assessment of the validity of questionnaires is not straight-
forward as there is no gold standard for outcome measure-
ment in PAD patients. In this study, we used clinical indices
retrospectively obtained from chart review, including the
presence of claudication and the Lee Risk Index as criterion
measures for clinical validity. This limitation should be kept
in mind together with the fact that no baseline health status
measurements were available when interpreting our results.
Future studies using the PAQ should further elaborate on
the clinical relevance of this disease-specific instrument
tracking clinical indices, such as the ankle-brachial index,
and aspects of lower-extremity functioning together with
patients’ health status.
In conclusion, this study demonstrated good clinical
validity of the PAQ as the instrument discriminated well
between patients with or without symptomatic PAD and its
severity and was sensitive to the presence of risk-factors
relevant for PAD. We would like to strengthen the impor-
tance of disease-specific health status measures like the
PAQ and advocate their use as outcome measure and
disease management tools in PAD management, rather
than relying on clinical measures alone. After all, outcome
and risk assessment should be evaluated from the patients’
perspective. Health status measures will play an increasingly
important role in the evaluation of diverse therapeutic
strategies and in clinical decision-making in the field of
vascular medicine.
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